• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Mylan

Pfizer agrees to pay $345M in EpiPen pricing lawsuit

July 16, 2021 By Sean Whooley

Pfizer (NYSE:PFE) agreed to pay $345 million to settle claims of overpayments for EpiPens due to alleged anti-competitive and unfair practices. Reuters reported that a filing disclosed in federal court in Kansas City, Kan., revealed the settlement set to resolve claims from consumers who say they overpaid for EpiPens with the alleged anti-competitive and unfair practices by […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceutical Tagged With: EpiPen, Mylan, Pfizer, Viatris

Kansas Distric Court rules in favor of Mylan in EpiPen class action

June 24, 2021 By Sean Whooley

Viatris (NSDQ:VTRS) announced that the U.S. District Court for the District of Kansas ruled in favor of Mylan in an EpiPen class action. Mylan, which Pfizer combined with its Upjohn business to form Viatris in November 2020, received a favorable ruling in substantial part that dismissed all of the plaintiffs’ claims under the federal RICO statute, including claims […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceutical Tagged With: Mylan, Viatris

DTW Podcast: CEO Johnson on entrepreneurship, upcoming MedtechColor Pitch Contest; Krum handicaps medtech Q4

February 1, 2021 By Tom Salemi

In this episode of the DeviceTalks Weekly Podcast, Angelique Johnson, CEO of MEMstim, shares her “accidental entrepreneur” story and how it has enabled her the help others pursuing the same dream. Also, Johnson, co-founder of MedtechColor, an organization seeking to further the advancement of people of color in the medical device industry, details the group’s […]

Filed Under: Device Talks Podcasts, Diabetes, Featured, Orthopedics, Surgical Robotics, Wall Street Beat Tagged With: Butterfly Network, Dexcom, Mylan, Stryker, Titan Surgical, Zimmer Biomet

Mylan must face EpiPen racketeering lawsuit

January 21, 2021 By Nancy Crotti

A federal judge in Minnesota has decided that Mylan must face a lawsuit accusing it of paying bribes and kickbacks to pharmacy benefit managers and of conspiring to fix prices on its EpiPen device. Drug wholesalers Rochester Drug CoOperative and Dakota Drug filed separate but similar lawsuits in March 2020 and June 2020, respectively, claiming that Mylan […]

Filed Under: Drug-Device Combinations, Featured, Legal News Tagged With: Mylan

Gilead licenses remdesivir production to 5 generic drugmakers

May 13, 2020 By Nancy Crotti

Gilead Sciences’ (NSDQ:GILD) said Tuesday that it has signed licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir, the experimental drug being used in the U.S. to treat COVID-19. The non-exclusive, voluntary agreements allow the companies — Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — […]

Filed Under: Business/Financial News, Distribution, Featured, Pharmaceutical Tagged With: Cipla, COVID-19, Drug Controller General of India, FDA, Ferozsons Laboratories, Gilead Sciences, Hetero Labs, Indian Council of Medical Research, Jubilant Lifesciences, Mylan

Teva launches generic EpiPen Jr.

August 20, 2019 By Sean Whooley

Teva (NYSE:TEVA) today announced that its FDA-approved generic EpiPen Jr. auto-injector is available in the U.S. The device wholesales to most retail pharmacies in packs of two for $300, or $150 per pen. Teva’s product is less than half the cost of Mylan’s non-generic EpiPen Jr., which lists at $643.89 per two-pack at Drugs.com. Get the full story at […]

Filed Under: Drug-Device Combinations, Pediatrics, Pharmaceutical Tagged With: Mylan, Teva Pharmaceuticals

Mylan agrees to settle SEC EpiPen probe for $30 million

July 31, 2019 By Nancy Crotti

Mylan (NSDQ:MYL) is nearing a $30 million settlement with the Securities and Exchange Commission (SEC) over an investigation involving the company’s EpiPen auto-injector and the Medicaid drug rebate program. The SEC probe was announced in 2016, shortly after Mylan agreed to pay $465 million to the U.S. Department of Justice to settle claims that it underpaid […]

Filed Under: Blog, Business/Financial News, Drug-Device Combinations, Featured, Legal News, News Well, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Mylan, Securities & Exchange Commission (SEC)

Pfizer to absorb Mylan in off-patent drug spinout

July 29, 2019 By Brad Perriello

Pfizer (NYSE:PFE) plans to absorb Mylan (NSDQ:MYL) as part of the spinout of its Upjohn off-patent drugs business in an all-stock deal. The deal, structured to avoid taxes on any gains from the spinout, would see each Mylan share converted into a share of the as-yet-unnamed new company. Pfizer stockholders would then own 57% of the new firm, […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: Mylan, Pfizer

Mylan shares fall on sales miss, swing to Q1 losses

May 7, 2019 By Danielle Kirsh

Mylan (NSDQ:MYL) posted first-quarter results today that missed the consensus revenue forecast on Wall Street, sending its share prices down. The Canonsburg, Penn.-based company swung to red ink for the three months ended March 31, reporting losses of -$25 million, or -5¢ per share, on a -7.0% sales decline to $2.5 billion, compared with Q1 2018. […]

Filed Under: Wall Street Beat Tagged With: Mylan

Mylan shares down on mixed Q4 results

February 27, 2019 By Sarah Faulkner

Shares in Mylan (NSDQ:MYL) fell yesterday after the company missed earnings expectations but beat sales estimates on Wall Street with its fourth-quarter financial results. The Pittsburgh, PA-based company posted profits of $51.2 million, or 10¢ per share, on sales of $3.04 billion for the three months ended Dec. 31, for bottom-line loss of -79% on sales loss […]

Filed Under: Business/Financial News, Drug-Device Combinations, MassDevice Earnings Roundup, Pharmaceutical, Wall Street Beat Tagged With: Mylan

Mylan launches generic sublingual film for opioid dependence

February 22, 2019 By Sarah Faulkner

Mylan (NSDQ:MYL) said today that it launched its buprenorphine and naloxone sublingual film as a generic of Indivior‘s (LON:INDV) Suboxone sublingual film. The product is indicated for the treatment of opioid dependence. The therapy should be used alongside counseling and psychosocial support for people living with opioid dependence, according to Mylan. Get the full story at our […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceutical, Wall Street Beat Tagged With: Dr. Reddy's Laboratories, indivior, Mylan

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 12
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy